New strength of Stalevo

Orion has launched a new strength of Stalevo which contains 200mg levodopa, 50mg carbidopa and 200mg entacapone.

Stalevo is indicated for the treatment of patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa carboxylase inhibitor treatment.

The additional strength has been launched to provide greater dosage flexibility to prescribers.

View Stalevo drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...